Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.

Ishizuka H, Toyama K, Yoshiba S, Okabe H, Furuie H.

Antimicrob Agents Chemother. 2012 Jul;56(7):3873-8. doi: 10.1128/AAC.06456-11. Epub 2012 Apr 23.

2.
3.

Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.

Ikematsu H, Kawai N.

Expert Rev Anti Infect Ther. 2011 Oct;9(10):851-7. doi: 10.1586/eri.11.112. Review.

PMID:
21973296
4.

Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.

Ishizuka H, Yoshiba S, Okabe H, Yoshihara K.

J Clin Pharmacol. 2010 Nov;50(11):1319-29. doi: 10.1177/0091270009356297. Epub 2010 Feb 9.

PMID:
20145259
5.

Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.

Koyama K, Nakai D, Takahashi M, Nakai N, Kobayashi N, Imai T, Izumi T.

Drug Metab Dispos. 2013 Jan;41(1):180-7. doi: 10.1124/dmd.112.048280. Epub 2012 Oct 22.

6.

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.

Sugaya N, Ohashi Y.

Antimicrob Agents Chemother. 2010 Jun;54(6):2575-82. doi: 10.1128/AAC.01755-09. Epub 2010 Apr 5.

7.

Identification of bioactivating enzymes involved in the hydrolysis of laninamivir octanoate, a long-acting neuraminidase inhibitor, in human pulmonary tissue.

Koyama K, Ogura Y, Nakai D, Watanabe M, Munemasa T, Oofune Y, Kubota K, Shinagawa A, Izumi T.

Drug Metab Dispos. 2014 Jun;42(6):1031-8. doi: 10.1124/dmd.114.057620. Epub 2014 Mar 28.

8.

Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.

Ishizuka H, Yoshiba S, Yoshihara K, Okabe H.

J Clin Pharmacol. 2011 Feb;51(2):243-51. doi: 10.1177/0091270010361914. Epub 2010 Mar 2.

PMID:
20197485
9.

Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects.

Shelton MJ, Lovern M, Ng-Cashin J, Jones L, Gould E, Gauvin J, Rodvold KA.

Antimicrob Agents Chemother. 2011 Nov;55(11):5178-84. doi: 10.1128/AAC.00703-11. Epub 2011 Sep 6.

10.

Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats.

Koyama K, Takahashi M, Nakai N, Takakusa H, Murai T, Hoshi M, Yamamura N, Kobayashi N, Okazaki O.

Xenobiotica. 2010 Mar;40(3):207-16. doi: 10.3109/00498250903447691.

PMID:
20146556
11.

High and continuous exposure of laninamivir, an anti-influenza drug, may work suppressively to generate low-susceptibility mutants in animals.

Kubo S, Tokumitsu A, Tomozawa T, Kakuta M, Yamashita M.

J Infect Chemother. 2012 Feb;18(1):69-74. doi: 10.1007/s10156-011-0292-4. Epub 2011 Sep 1.

PMID:
21881920
12.

Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.

Kakuta M, Kubo S, Tanaka M, Tobiume S, Tomozawa T, Yamashita M.

Antiviral Res. 2013 Oct;100(1):190-5. doi: 10.1016/j.antiviral.2013.08.004. Epub 2013 Aug 15.

PMID:
23954190
13.

Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance.

Kashiwagi S, Yoshida S, Yamaguchi H, Mitsui N, Tanigawa M, Shiosakai K, Yamanouchi N, Shiozawa T, Yamaguchi F.

J Infect Chemother. 2013 Apr;19(2):223-32. doi: 10.1007/s10156-012-0481-9. Epub 2012 Oct 20.

PMID:
23085742
14.

Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial.

Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y; MARVEL Study Group.

Clin Infect Dis. 2010 Nov 15;51(10):1167-75. doi: 10.1086/656802. Epub 2010 Oct 11.

PMID:
20936975
15.

Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza.

Yamashita M.

Antivir Chem Chemother. 2010;21(2):71-84. doi: 10.3851/IMP1688. Review.

PMID:
21107016
16.

Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.

Housman ST, Pope JS, Russomanno J, Salerno E, Shore E, Kuti JL, Nicolau DP.

Antimicrob Agents Chemother. 2012 May;56(5):2627-34. doi: 10.1128/AAC.05354-11. Epub 2012 Feb 13.

17.

Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration.

Kubo S, Tomozawa T, Kakuta M, Tokumitsu A, Yamashita M.

Antimicrob Agents Chemother. 2010 Mar;54(3):1256-64. doi: 10.1128/AAC.01311-09. Epub 2010 Jan 4.

18.

Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.

Panozzo J, Oh DY, Margo K, Morton DA, Piedrafita D, Mosse J, Hurt AC.

Antiviral Res. 2015 Aug;120:66-71. doi: 10.1016/j.antiviral.2015.05.007. Epub 2015 May 26.

PMID:
26022199
19.

Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.

Kashiwagi S, Watanabe A, Ikematsu H, Awamura S, Okamoto T, Uemori M, Ishida K.

J Infect Chemother. 2013 Aug;19(4):740-9. doi: 10.1007/s10156-013-0622-9. Epub 2013 Jun 4.

20.

Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation.

McKimm-Breschkin JL, Barrett S.

Antiviral Res. 2015 Feb;114:62-6. doi: 10.1016/j.antiviral.2014.12.004. Epub 2014 Dec 9.

PMID:
25499124

Supplemental Content

Support Center